182 related articles for article (PubMed ID: 11865075)
1. Erythropoietin, tumours and the von Hippel-Lindau gene: towards identification of mechanisms and dysfunction of oxygen sensing.
Wiesener MS; Eckardt KU
Nephrol Dial Transplant; 2002 Mar; 17(3):356-9. PubMed ID: 11865075
[No Abstract] [Full Text] [Related]
2. Molecular pathogenesis of the von Hippel-Lindau hereditary cancer syndrome: implications for oxygen sensing.
Yang H; Kaelin WG
Cell Growth Differ; 2001 Sep; 12(9):447-55. PubMed ID: 11571227
[No Abstract] [Full Text] [Related]
3. VHL and kidney cancer.
Ohh M; Kaelin WG
Methods Mol Biol; 2003; 222():167-83. PubMed ID: 12710686
[No Abstract] [Full Text] [Related]
4. Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells.
Gorospe M; Egan JM; Zbar B; Lerman M; Geil L; Kuzmin I; Holbrook NJ
Mol Cell Biol; 1999 Feb; 19(2):1289-300. PubMed ID: 9891063
[TBL] [Abstract][Full Text] [Related]
5. The kidney and von Hippel-Lindau disease: impact of molecular genetic analysis of the VHL gene for clinical management.
Neumann HP; Bender BU; Schultze-Seemann W; Krause T; Altehoefer C; Scheremet R; Orszagh M; Schwarzkopf G; Januszewicz A; Janetschek G; Riegler P
Contrib Nephrol; 1997; 122():102-8. PubMed ID: 9399049
[No Abstract] [Full Text] [Related]
6. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
Petrella BL; Lohi J; Brinckerhoff CE
Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
[TBL] [Abstract][Full Text] [Related]
7. Germline and somatic mutations in von Hippel-Lindau disease gene and its significance in the development of kidney cancer.
Shuin T; Kondo K; Ashida S; Okuda H; Yoshida M; Kanno H; Yao M
Contrib Nephrol; 1999; 128():1-10. PubMed ID: 10597373
[No Abstract] [Full Text] [Related]
8. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
9. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
10. Radiological evaluation, management, and surveillance of renal masses in Von Hippel-Lindau disease.
Meister M; Choyke P; Anderson C; Patel U
Clin Radiol; 2009 Jun; 64(6):589-600. PubMed ID: 19414081
[TBL] [Abstract][Full Text] [Related]
11. [Current progress in the diagnosis and treatment of renal cell carcinoma].
Tsukamoto T; Takahashi A; Kitamura H
Nihon Jinzo Gakkai Shi; 2002 Dec; 44(8):779-85. PubMed ID: 12607966
[No Abstract] [Full Text] [Related]
12. von Hippel-Lindau disease: genetic and clinical observations.
Iliopoulos O
Front Horm Res; 2001; 28():131-66. PubMed ID: 11443850
[No Abstract] [Full Text] [Related]
13. Von Hippel-Lindau disease: the role of gene analysis in affected families.
Riegler P; Huber W; Corradini R; Neumann HP; Glaesker S; Sessa A
Nephron; 2000 Jan; 84(1):95-7. PubMed ID: 10644921
[No Abstract] [Full Text] [Related]
14. [VHL, angiogenesis and renal carcinoma: the puzzle is complete].
Richard S
Ann Pathol; 2000 Mar; 20(2):107-9. PubMed ID: 10740003
[No Abstract] [Full Text] [Related]
15. Mutational analysis of endothelial cells derived from von Hippel-Lindau-related renal cancer.
Los M; Kerckhaert OA; Zewald R; van Amstel HK; Voest EE
J Natl Cancer Inst; 2000 Oct; 92(20):1688-9. PubMed ID: 11036115
[No Abstract] [Full Text] [Related]
16. Molecular basis of the VHL hereditary cancer syndrome.
Kaelin WG
Nat Rev Cancer; 2002 Sep; 2(9):673-82. PubMed ID: 12209156
[TBL] [Abstract][Full Text] [Related]
17. The challenge of kidney lesions in von Hippel-Lindau disease.
Neumann HP; Riegler P; Huber W; Corradini R; Sessa A; Fontana D; Wetterauer U; Janetschek G
Contrib Nephrol; 2001; (136):193-207. PubMed ID: 11688380
[No Abstract] [Full Text] [Related]
18. Analysis of von Hippel-Lindau hereditary cancer syndrome: implications of oxygen sensing.
Yang H; Ivan M; Min JH; Kim WY; Kaelin WG
Methods Enzymol; 2004; 381():320-35. PubMed ID: 15063684
[No Abstract] [Full Text] [Related]
19. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
Sufan RI; Jewett MA; Ohh M
Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
[TBL] [Abstract][Full Text] [Related]
20. Clinical review 155: Pheochromocytoma in Von Hippel-Lindau disease.
Hes FJ; Höppener JW; Lips CJ
J Clin Endocrinol Metab; 2003 Mar; 88(3):969-74. PubMed ID: 12629069
[No Abstract] [Full Text] [Related]
[Next] [New Search]
